In more detail, six studies have investigated the efficacy of evolocumab or alirocumab on LDL-C levels in pediatric cohorts of FH, and the results on therapeutic efficacy demonstrated great variability, which may reflect the variability of LDL receptor activity as a result of the heterogenous genetic profile of the patients. Here, LDLR is linked to familial hyperaldosteronism.